Updated:
Flex Pharma
Flex Pharma is a family office headquartered in Larchmont, New York, with offices across the US and Germany. No public AUM or portfolio details.
Flex Pharma
Flex Pharma is a family office based in Larchmont, New York, with additional offices in Pasadena, New York City, Boston, San Diego, Indianapolis, Menlo Park, and Heidelberg, Germany. Its founding year and wealth origin are not publicly disclosed, making it an unusually private entity among family offices. The firm's investment strategy and allocation preferences are not documented in any public source. No confirmed asset classes, stage preferences, or deal structures have been reported. No named portfolio companies, co-investors, or external fund commitments have been identified through public records. Team size, deployment numbers, and philanthropic vehicles are unknown. No recent operational events have been captured in media or filings. The firm maintains no publicly accessible website or LinkedIn presence, contributing to its low profile. The primary structural differentiator is its fragmented physical footprint across eight locations, suggesting a distributed or networked operational model. However, without any confirmed activities or principals, its actual structure and mandate remain opaque.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Larchmont
Corporate office
Larchmont, NY, United States
Additional offices
Pasadena · New York · Boston · San Diego · Indianapolis · Menlo Park · Heidelberg
Frequently asked questions
Who runs investment decisions at Flex Pharma?
No individual principals, investment committee members, or decision-makers have been publicly identified for Flex Pharma. The firm does not have a confirmed CEO, CIO, or managing principal on record.
How does Flex Pharma source proprietary deal flow?
Flex Pharma's deal sourcing model is undisclosed. The firm has no public deal activity, partnership announcements, or representation in industry databases, making its sourcing approach unverifiable.
Is Flex Pharma structured as a single family office or multi-family office?
The firm's structure is not confirmed publicly. Its name and location suggest a single-family office, but no documentation or media coverage supports this classification.
Does Flex Pharma participate in fund commitments or only direct deals?
No public information exists regarding Flex Pharma's investment vehicle preferences. Whether the firm makes fund commitments or direct investments is unknown.
What investment stages does Flex Pharma typically target?
Flex Pharma's stage preferences, if any, have not been disclosed. No seed, venture, growth, or buyout activity has been reported.
Which sectors does Flex Pharma explicitly avoid?
The firm has not published any sector avoidance criteria. Its investment universe is entirely opaque.
Where does the underlying wealth come from?
The wealth origin for Flex Pharma is not publicly disclosed. No family or individual has been named as the source of capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: